| Ikaria® Begins Enrollment of Pivotal Trial for LUCASSIN® - PR Newswire (press release) |
|
|
PR Newswire (press release) It is characterized by rapid onset of renal failure with a high mortality rate that exceeds 80% within three months. The REVERSE Trial will compare |